Welcome to our dedicated page for Absci news (Ticker: ABSI), a resource for investors and traders seeking the latest updates and insights on Absci stock.
Absci Corporation develops generative AI-designed biologic therapeutics as a clinical-stage biopharmaceutical company. News about ABSI centers on its Integrated Drug Creation platform, internal prolactin and prolactin receptor (PRLR) programs, and clinical development of ABS-201, an anti-PRLR antibody being developed for androgenetic alopecia and endometriosis.
Recurring updates cover HEADLINE trial safety, tolerability and pharmacokinetic disclosures, preclinical pipeline additions such as ABS-202, business and operating results, clinical advisory activity, healthcare conference participation, executive leadership changes, and Nasdaq inducement equity grants.
Absci (Nasdaq: ABSI) reported its Q1 2024 financial and operational results, highlighting key advancements in its drug creation programs. The company initiated IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody, and progressed ABS-201 and ABS-301 through preclinical stages. Absci completed an $86.4 million public offering in March 2024, enhancing its financial position. Despite a decline in revenue to $0.9 million from $1.3 million year-over-year, net loss decreased from $23.4 million to $22.0 million. R&D expenses lowered to $12.2 million, and SG&A expenses reduced to $8.7 million. Absci's cash, equivalents, and short-term investments stood at $161.5 million as of March 31, 2024, expected to fund operations into H1 2027.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.